NCT06189157RECRUITINGanonymous

An Open-label Phase I/IIa, Multicentre, Interventional Single-arm Trial of MB-CART19.1 in Patients With Refractory SLE

Sponsor

Source record

Miltenyi Biomedicine GmbH

Phase

Source record

PHASE1

Modality

AI-normalized

protein therapy

Target

AI-normalized

MB-CART19.1

Indication / condition

AI-normalized

SLE - Systemic Lupus Erythematosus

Intervention

Source record

MB-CART19.1

Related intelligence directories

Indication directory: SLE - Systemic Lupus Erythematosus Modality directory: protein therapy Target directory: MB-CART19.1

Source & freshness

Source record

NCT ID

NCT06189157

Original source

ClinicalTrials.gov

Source last updated

Detailed source ingestion pending.

Ingested at

Jul 24, 2026

Internal sync

Jul 24, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT06189157

Title

An Open-label Phase I/IIa, Multicentre, Interventional Single-arm Trial of MB-CART19.1 in Patients With Refractory SLE

Sponsor

Miltenyi Biomedicine GmbH

Status

RECRUITING

Phase

PHASE1

Condition raw

SLE - Systemic Lupus Erythematosus

Condition normalized

SLE - Systemic Lupus Erythematosus

Modality raw

protein therapy

Modality normalized

protein therapy

Target raw

MB-CART19.1

Target normalized

MB-CART19.1

Interventions

MB-CART19.1

Public preview

Source record

An Open-label Phase I/IIa, Multicentre, Interventional Single-arm Trial of MB-CART19.1 in Patients With Refractory SLE is a PHASE1 clinical asset sponsored by Miltenyi Biomedicine GmbH in SLE - Systemic Lupus Erythematosus. SEO and diligence focus: MB-CART19.1, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

Investment-Ready Snapshot

An Open-label Phase I/IIa, Multicentre, Interventional Single-arm Trial of MB-CART19.1 in Patients With Refractory SLE is a PHASE1 clinical asset sponsored by Miltenyi Biomedicine GmbH in SLE

Systemic Lupus Erythematosus. SEO and diligence focus: MB-CART19.1, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

An Open-label Phase I/IIa, Multicentre, Interventional Single-arm Trial of MB-CART19.1 in Patients With Refractory SLE

Source & freshness

Public preview

Create an account to unlock this report

An Open-label Phase I/IIa, Multicentre, Interventional Single-arm Trial of MB-CART19.1 in Patients With Refractory SLE

Investment-Ready Snapshot

Provenance

Protocol Description

Outcome Measures

Eligibility

Known Results And Readout Context

Patent And IP Landscape

Contacts